Eli Lilly and Company $LLY Shares Acquired by PTM Wealth Management LLC

PTM Wealth Management LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 10.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 524 shares of the company’s stock after buying an additional 50 shares during the quarter. Eli Lilly and Company comprises 0.3% of PTM Wealth Management LLC’s holdings, making the stock its 28th largest position. PTM Wealth Management LLC’s holdings in Eli Lilly and Company were worth $409,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Duquesne Family Office LLC boosted its holdings in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at approximately $570,000. LS Investment Advisors LLC raised its position in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after purchasing an additional 40 shares in the last quarter. Cutter Capital Management LP purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $14,866,000. Finally, Prism Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $207,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $748.26 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business’s 50 day moving average is $740.54 and its 200-day moving average is $774.30. The stock has a market cap of $708.20 billion, a PE ratio of 48.91, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s payout ratio is currently 39.22%.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $941.35.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.